Thromboembolism

Not only does Evista cause lethal blood clots -- its warning label says "Increased risk of Venous Thromboembolism and Death From Stroke" -- it increases the risk of ovarian cancer say some clinicians.

FDA Official Leaves as He Came in: Serving Wall Street 2007

"Thromboembolism and the effects are very significant," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.

Yahoo! News: Business - Opinion 2012

RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) - Dabigatran etexilate was non-inferior to warfarin (target INR 2.0 to 3.0) in preventing recurrent symptomatic VTE or VTE-related death (1) - Thirty-seven percent fewer

WN.com - Articles related to ‘SMS therapy’ for chronic diseases 2010

The Pharmacor 2010 findings from the topic entitled Venous Thromboembolism reveal that the dominance that low-molecular-weight heparins have held in the venous thromboembolism drug market will be severely reduced over the next decade, following the introduction and deep market penetration of several novel oral agents.

THE MEDICAL NEWS Editors 2010

RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) - Dabigatran etexilate was non-inferior to warfarin (target INR 2.0 to 3.0) in preventing recurrent symptomatic VTE or VTE-related death (1) - Thirty-seven percent fewer

WN.com - Articles related to Alcohol Addiction - complications and adverse side effects 2010

RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) - Dabigatran etexilate was non-inferior to warfarin (target INR 2.0 to 3.0) in preventing recurrent symptomatic VTE or VTE-related death (1) - Thirty-seven percent fewer

WN.com - Articles related to ‘SMS therapy’ for chronic diseases 2010

The Pharmacor 2010 findings from the topic entitled Venous Thromboembolism reveal that the dominance that low-molecular-weight heparins have held in the venous thromboembolism drug market will be severely reduced over the next decade, following the introduction and deep market penetration of several novel oral agents.

THE MEDICAL NEWS Editors 2010

This "Prior Approval" supplemental new drug application provides for the addition of new information in the Thromboembolism subsection of the Thromboembolic Disorders and other Vascular Problems subsection of WARNINGS.

Trial Lawyer Resource Center Mark Zamora 2010

Venous Thromboembolism - Drug Pipeline Analysis and Market Forecasts to 2016, which provides key data, information and analysis on the VTE market.

The Earth Times Online Newspaper 2010

RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) - Dabigatran etexilate was non-inferior to warfarin (target INR 2.0 to 3.0) in preventing recurrent symptomatic VTE or VTE-related death (1) - Thirty-seven percent fewer

WN.com - Articles related to Texting can improve medication use and chronic disease treatment 2010